Details

Autor(en) / Beteiligte

• Baradaran-Heravi, Alireza
• Raams, Anja
• Lubieniecka, Joanna
• Cho, Kyoung Sang
• DeHaai, Kristi A.
• Basiratnia, Mitra
• Mari, Pierre-Olivier
• Xue, Yutong
• Rauth, Michael
• Olney, Ann Haskins
• Shago, Mary
• Choi, Kunho
• Weksberg, Rosanna A.
• Nowaczyk, Malgorzata J.M.
• Wang, Weidong
• Jaspers, Nicolaas G.J.
• Boerkoel, Cornelius F.

Titel

SMARCAL1 deficiency predisposes to non-Hodgkin lymphoma and hypersensitivity to genotoxic agents in vivo

Ist Teil von

• American journal of medical genetics. Part A, 2012-09, Vol.158A (9), p.2204-2213

Ort / Verlag

Hoboken: Wiley Subscription Services, Inc., A Wiley Company

Erscheinungsjahr

2012

Quelle

Wiley-Blackwell Journals

Beschreibungen/Notizen

• Schimke immuno‐osseous dysplasia (SIOD) is a multisystemic disorder with prominent skeletal, renal, immunological, and ectodermal abnormalities. It is caused by mutations of SMARCAL1 (SWI/SNF‐related, matrix‐associated, actin‐dependent regulator of chromatin, subfamily a‐like 1), which encodes a DNA stress response protein. To determine the relationship of this function to the SIOD phenotype, we profiled the cancer prevalence in SIOD and assessed if defects of nucleotide excision repair (NER) and nonhomologous end joining (NHEJ), respectively, explained the ectodermal and immunological features of SIOD. Finally, we determined if Smarcal1del/del mice had hypersensitivity to irinotecan (CPT‐11), etoposide, and hydroxyurea (HU) and whether exposure to these agents induced features of SIOD. Among 71 SIOD patients, three had non‐Hodgkin lymphoma (NHL) and one had osteosarcoma. We did not find evidence of defective NER or NHEJ; however, Smarcal1‐deficient mice were hypersensitive to several genotoxic agents. Also, CPT‐11, etoposide, and HU caused decreased growth and loss of growth plate chondrocytes. These data, which identify an increased prevalence of NHL in SIOD and confirm hypersensitivity to DNA damaging agents in vivo, provide guidance for the management of SIOD patients. © 2012 Wiley Periodicals, Inc.